NCT06352437View on ClinicalTrials.gov

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

June 10, 2024

Primary Completion Date

October 5, 2025

Study Completion Date

October 5, 2025

Conditions
Healthy
Interventions
DRUG

BI 3034701

BI 3034701

DRUG

Placebo matching BI 3034701

Placebo matching BI 3034701

Trial Locations (1)

10117

Charité Research Organisation GmbH, Berlin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06352437 - A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity | Biotech Hunter | Biotech Hunter